ArticleCancer immunology, immunotherapy : CII2025
Molecular mimicry between parasites and cancer: a novel approach for developing cancer vaccines and therapeutic antibodies.
Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- Glancing at the role of Toxoplasma gondii in neuro-oncology: from risk factor to therapeutic target.Infectious agents and cancer · 2026Review
- Parasite in cancer therapy: molecular mechanisms and translational potential.Frontiers in immunology · 2026Review
- Parasites' immunomodulators: a breakthrough in immunotherapeutics displaying antineoplastic activity against human colorectal and hepatocellular carcinoma cells.Infectious agents and cancer · 2025Article
- Bridging the gap for diverse applications of parasites as advanced cancer therapeutics: current progress and future directions.Infectious agents and cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is one of the most dreaded diseases worldwide. Conventional treatments such as surgery, chemotherapy, and radiotherapy have limitations and adverse effects. Cancer immunotherapy and targeted therapies offer new treatment options. Parasite-based cancer therapy shows promise in fighting tumors. Some parasites have anti-cancer properties through multi-mechanistic strategies, with the molecular mimicry theory as a leading explanation for parasites' anti-cancer effects. This study aimed to explore the existence of shared antigenic proteins between parasites (Trichinella spiralis, Schistosoma mansoni, and Toxoplasma gondii) and cancer cell lines (MCF-7 human breast cancer and A549 human lung cancer). Polyclonal antisera against T. spiralis, S. mansoni, and T. gondii parasites were generated in rabbits. Antibody reactivity with extracts of MCF-7 and A549 cancer cells was detected using SDS-PAGE and immunoblotting. Results documented the molecular mimicry between parasites and cancers as it revealed cross-reactive bands when using T. spiralis antibodies against MCF-7 and A549 cancer cell extracts at approximate molecular weights of 70 and 35 kDa, and with S. mansoni antibodies at an approximate molecular weight of 80 kDa. Toxoplasma gondii antibodies neither reacted with MCF-7 human breast cancer nor A549 human lung cancer cell extracts. Results of this study could establish a foundation for subsequent investigation among a broad range of parasites for molecular mimicry with cancers. Identification, molecular characterization, and investigation of the anti-neoplastic activity of these cross-reactive antigens could shed light on new pathways for the potential development of a novel class of innovative cancer vaccine candidates and therapeutic antibodies of parasitic origin for cancer immunotherapy and targeted therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.